Skip to main content

News

June 15, 2020
Targeted chemo is feasible, safe, and may improve quality of life.
November 12, 2018
Results of a new study showed that AFP categories agreed moderately with mRECIST outcomes and yielded accurate prognostic prediction in patients with unresectable hepatocellular carcinoma and AFP levels ≥400 ng/mL treated with chemoembolization.
November 08, 2018
A concentrated dose of anti-CEA CAR-T cells administered precisely at the site of a solid tumor by Pressure-enabled Drug Delivery (PEDD) is safe, with encouraging clinical responses, according to the results of a phase 1b clinical trial.
November 05, 2018
In patients with ultrasound-invisible early stage hepatocellular carcinoma, the combined therapy of conventional transarterial chemoembolization followed by fluoroscopy-guided radiofrequency ablation was safe and effective resulting in less local…
October 31, 2018
A nomogram including 6 pre-Y90 radioembolization (RAE) parameters predicted overall survival (OS) post-RAE in patients with colorectal cancer liver metastases.
October 28, 2018
For the treatment of patients with unresectable hepatocellular carcinoma, the combination of TACE with iodine [131I] metuximab infusion may improve local efficacy and overall survival when compared with TACE alone.
October 21, 2018
A new study sought to determine if patient and facility demographics impacted overall survival in patients with early-stage non-small cell lung cancer treated with radiofrequency ablation.
October 14, 2018
Computed tomography-guided percutaneous microwave ablation is safe and well-tolerated in patients with renal cell carcinoma and achieves nephron preservation similar to existing ablative modalities.
October 14, 2018
A new study found that Y90 radioembolization with glass microspheres given at a boosted dose in patients with large hepatocellular carcinomas (HCCs) may show favorable tumor response.
October 03, 2018
Percutaneous image-guided core needle biopsies in tumor >2 cm are safe and effective in obtaining tumour genetic material, according to a study published in the European Journal of Cancer.
September 30, 2018
A new study that looked at outcomes of surgical resection after yttrium-90 (Y90) transarterial radioembolization (TARE) in patients with hepatocellular carcinoma found that TARE can serve as a safe bridge to resection.
Back to Top